Skip to main content
logo
Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden flag Sweden · Delayed Price · Currency is SEK
5.33
+0.06 (1.14%)
Jun 12, 2026, 5:29 PM CET

Hemas Holdings Revenue

Egetis Therapeutics AB had revenue of 13.40M SEK in the quarter ending March 31, 2026, with 5.51% growth. This brings the company's revenue in the last twelve months to 63.10M, up 35.12% year-over-year. In the year 2025, Egetis Therapeutics AB had annual revenue of 62.40M with 35.36% growth.

Revenue (ttm)
63.10M
Revenue Growth
+35.12%
P/S Ratio
39.01
Revenue / Employee
1.43M
Employees
44
Market Cap
2.46B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202562.40M16.30M35.36%
Dec 31, 202446.10M-11.50M-19.97%
Dec 31, 202357.60M35.00M154.87%
Dec 31, 202222.60M-15.60M-40.84%
Dec 31, 202138.20M-2.46M-6.05%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Saniona AB429.29M
BioInvent International AB217.86M
Hansa Biopharma AB190.49M
Genovis AB (publ.)131.09M
Oncopeptides AB83.24M
Medivir AB9.01M
Vicore Pharma Holding AB3.53M
Flerie AB1.80M
Revenue Rankings

Egetis Therapeutics AB News

More News